Please assess the completion status of the following clinical trial:

Trial Title: Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with an existing diagnosis of diabetes mellitus, of any type, defined as having a fasting plasma glucose (FPG) \> 126 mg/dL, or hemoglobin A1c (HbA1c) \> 6.5%.~* Ability to provide informed consent for participation.~Exclusion Criteria:~* Individuals who do not have diabetes.~* Those who have an allergy to pilocarpine.~* Frequent episodes of low blood sugar (hypoglycemia), have no warning symptoms of hypoglycemia (hypoglycemia unawareness), or are at high risk of having hypoglycemia.~* If taking any of the following medications: any beta-blockers (including atenolol, carvedilol, metoprolol, and propanolol), chlorthalidone, hydrochlorothiazide, oxybutynin, and tiotropium.~* Individuals who have the following conditions, for which it is not safe to take pilocarpine, including:~Known or suspected gallstones or gallbladder disease~Kidney stones~Conditions that affect your thinking and/or memory, including Parkinson's disease and Alzheimer's disease~Asthma~Chronic obstructive pulmonary disease (COPD)~Glaucoma~Irritable Bowel Syndrome~Pregnancy - a pregnancy test will be obtained for each woman of child-bearing age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Diabetes (Type: EXPERIMENTAL): All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).